Hypokalemic paralysis secondary to tenofovir induced fanconi syndrome
نویسندگان
چکیده
منابع مشابه
Secondary Sjogren's syndrome presenting with hypokalemic periodic paralysis
Renal tubular acidosis (RTA) may develop in a large population of patients with Sjogren's syndrome (SS), but most of the subjects are asymptomatic. Here, we report a patient with known rheumatoid arthritis and symptoms of xerostomia, xerophthalmia and periodic paralysis. SS should be considered as a cause of RTA. The treatment of the underlying disorder may ameliorate the symptoms.
متن کامل[Secondary hypokalemic paralysis in adult with hypertension].
Hypokalemic paralysis (HP) is a very uncommon condition. Few publications are available on the subject, and these are mainly case reports or small series. A patient with HP who experienced a complete recovery is reported. A 62-year-old male Caucasian patient attended the emergency room for progressive strength loss. His clinical history included morbid obesity, high blood pressure (HBP), and dy...
متن کاملHypokalemic paralysis revealing Sjögren's syndrome (case report)
Case report A 16-year old girl presented with rapid onset of progressing muscular weakness, dysphagia, dysphonia and significant wasting. She lost 13 kg during the last year. On examination she was dystrophic (BMI 15,7) and had clinical signs of severe myopathy. Laboratory findings confirmed myopathy (CPK 106,4 ukat/L, ALT 0,96 ukat/l, AST 2,86 ukat/L, myoglobin 1582 ug/L), inflammatory markers...
متن کاملSjogren's syndrome presenting with hypokalemic periodic paralysis.
We report a rare case of a 38-year-old female who presented with sudden onset flaccid quadriplegia and respiratory arrest with no significant past clinical history. She was later found to have hypokalemia due to distal renal tubular acidosis and further diagnosed as case of Sjogrens Syndrome.
متن کاملHypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy
Introduction of immune checkpoint inhibitors (ICIs) has led to significant improvements in the treatment of multiple malignancies. Anti-programmed cell death protein 1 (PD-1) and anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) are two essential ICIs that have been FDA approved since 2011. As the use of immunotherapy in melanoma and other malignancies increases, the potential of adverse events al...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Indian Journal of Sexually Transmitted Diseases and AIDS
سال: 2015
ISSN: 0253-7184
DOI: 10.4103/0253-7184.167176